Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.
about
Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trialsGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyRecommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon.Treating and preventing no reflow in the cardiac catheterization laboratory.Primary percutaneous coronary intervention in the Isfahan province, Iran; A situation analysis and needs assessment.Percutaneous coronary intervention and the no-reflow phenomenon.Ischemic post-conditioning and vasodilator therapy during standard cardiopulmonary resuscitation to reduce cardiac and brain injury after prolonged untreated ventricular fibrillation.Management of 'no-reflow' complicating reperfusion therapy.Insulin says NO to cardiovascular disease.Unanticipated signaling events associated with cardiac adenylyl cyclase gene transfer.The management of thrombotic lesions in the cardiac catheterization laboratory.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventiThe challenges and impact of microvascular injury in ST-elevation myocardial infarction.Developing drugs for use before, during and soon after percutaneous coronary intervention.An update on coronary bypass graft intervention.Early Administration of Intracoronary Nitroprusside Compared with Thrombus Aspiration in Myocardial Perfusion for Acute Myocardial Infarction: A 3-Year Clinical Follow-Up StudyComplications of coronary intervention: device embolisation, no-reflow, air embolism.Exogenous nitric oxide requires an endothelial glycocalyx to prevent postischemic coronary vascular leak in guinea pig hearts.Treating acute "no-reflow" with intracoronary adenosine in 4 patients during percutaneous coronary intervention.Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarctionLeft circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease.Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry.Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center.Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.Comparison of different methods of ST segment resolution analysis for prediction of 1-year mortality after primary angioplasty for acute myocardial infarction.Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.
P2860
Q27013629-08332A72-A489-479A-A447-21B92B3193AEQ28239975-0F7D2A6D-E403-4EF6-BD39-34775031D913Q35582491-A769722B-69A8-4A76-B6C3-5AA6E8FBF18BQ35892175-A326B906-1FA8-4B14-9125-A8B7D24B8C39Q36302125-8F025501-C93F-4BFC-B0AB-F4F8D773C600Q36841685-633AE70B-6614-4392-BC87-62133EB12201Q36867295-7CA0E1C9-7CF2-484B-AA6C-3684783D0228Q36980179-C22D82EA-07B8-44A2-9DAE-F3C6DD3583D5Q37152013-0636822C-252C-4B23-B9BB-0AFF5FD9CF3CQ37807194-FEE8B9D2-210F-4BD2-BF05-ED891B9B1520Q37847462-AA00239E-CB27-4927-B86C-E28D1EAB76BFQ37947959-BD497773-795D-498F-8EE3-20B0C9BC3C76Q37953885-1D1E24F1-4997-4538-BDF6-31B79BDE3169Q38705817-2E8A7422-CB48-47D1-BD11-145F4C695C2AQ38708145-0FA8FA0E-CC91-44E6-999C-CC3448970634Q38871749-C67F101C-B1F6-481F-AB69-C5D8581E9838Q39399631-78606217-AF13-4106-9CC9-CC69370A90EEQ39667935-83A0ECCD-F9E4-427C-9ED1-8A9AB1FCC3B4Q40823884-A9BF180B-FF1A-4024-8BCE-34FE02217C02Q41982365-54CEDB36-8036-4B01-B8B3-FC66E44A1610Q42078342-C62EE821-4556-41D1-AAAB-15DC45E0A217Q46260031-77D79E07-3D2B-4A67-8604-AA60BD573E87Q46662897-0DFCFD55-FABE-473A-A06A-1C5D3DD758C8Q48264897-21EFFE26-3616-45F6-BD23-EB5519E3286CQ50553816-3E128CAF-9C61-4E94-AC65-EE6A4F631082Q51068099-B383E730-73DB-413C-BE90-8499A6DFE9DAQ51369856-65D667E2-B49D-4C86-92B3-2C2DB0E7224CQ54979759-8FE696E2-B493-42A3-BF4C-B95798BE6ED7
P2860
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Treatment of no-reflow and imp ...... ial human clinical experience.
@en
type
label
Treatment of no-reflow and imp ...... ial human clinical experience.
@en
prefLabel
Treatment of no-reflow and imp ...... ial human clinical experience.
@en
P2093
P1476
Treatment of no-reflow and imp ...... ial human clinical experience.
@en
P2093
P304
P356
10.1016/S0735-1097(01)01138-X
P407
P577
2001-04-01T00:00:00Z